Evidence map›Paper›PMID 39795818›Full record

ReviewMaterials (Basel, Switzerland)2025

Current Strategies in Developing Antibacterial Surfaces for Joint Arthroplasty Implant Applications.

Giovana Collombaro Cardoso, Diego Rafael Nespeque Correa, Marco Fosca, Evgenii V Pometun, Iulian V Antoniac, Carlos Roberto Grandini, Julietta V Rau

Abstract readReview
In one paragraph

Review in Materials (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Giovana Collombaro CardosoLaboratório de Anelasticidade e Biomateriais, UNESP-Universidade Estadual Paulista, Bauru 17.033-360, SP, Brazil.ORCID 0000-0003-3854-5631
Diego Rafael Nespeque CorreaLaboratório de Anelasticidade e Biomateriais, UNESP-Universidade Estadual Paulista, Bauru 17.033-360, SP, Brazil.ORCID 0000-0002-1803-6488
Marco FoscaIstituto di Struttura della Materia, Consiglio Nazionale delle Ricerche (ISM-CNR), Via del Fosso del Cavaliere 100, 00133 Rome, Italy.ORCID 0000-0003-0962-8083
Evgenii V PometunDepartment of Analytical, Physical and Colloid Chemistry, Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University, Trubetskaya 8, Build. 2, Moscow 119048, Russia.ORCID 0000-0003-3750-4408
Iulian V AntoniacFaculty of Material Science and Engineering, National University of Science and Technology Politehnica Bucharest, 313 Splaiul Independentei, District 6, RO-060042 Bucharest, Romania.ORCID 0000-0003-0112-3494
Carlos Roberto GrandiniLaboratório de Anelasticidade e Biomateriais, UNESP-Universidade Estadual Paulista, Bauru 17.033-360, SP, Brazil.ORCID 0000-0002-3336-309X
Julietta V RauIstituto di Struttura della Materia, Consiglio Nazionale delle Ricerche (ISM-CNR), Via del Fosso del Cavaliere 100, 00133 Rome, Italy.ORCID 0000-0002-7953-1853

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico #404020/2023-2Fundação Coordenação de Aperfeiçoamento de Pessoal de Nível Superior #88887.716787/2022-00Fundação Coordenação de Aperfeiçoamento de Pessoal de Nível Superior #88887.898681/2023-00Fundação de Amparo à Pesquisa do Estado de São Paulo #2021/15018-9Fundação de Amparo à Pesquisa do Estado de São Paulo #2024/03148-3
6 · The paper itself

Abstract

Prosthetic joint infections (PJIs) remain a significant challenge, occurring in 1% to 2% of joint arthroplasties and potentially leading to a 20% to 30% mortality rate within 5 years. The primary pathogens responsible for PJIs include Staphylococcus aureus, coagulase-negative staphylococci, and Gram-negative bacteria, typically treated with intravenous antibiotic drugs. However, this conventional approach fails to effectively eradicate biofilms or the microbial burden in affected tissues. As a result, innovative strategies are being explored to enhance the efficacy of infection prevention through the development of antibacterial-coated implants. These coatings are required to demonstrate broad-spectrum antimicrobial activity, minimal local and systemic toxicity, favorable cost-effectiveness, and support for bone healing. In the present review, the analysis of various methodologies for developing antibacterial coatings was performed, emphasizing studies that conducted in vivo tests to advance potential clinical applications. A diversity of techniques employed for the development of coatings incorporating antimicrobial agents highlights promising avenues for reducing infection-related surgical failures.

Indexed as

antibacterial coatingsantibacterial surfacesantimicrobial coatingsbiomedical implantsimplantssurface treatments

Identifiers

PMID39795818
PMCPMC11722469

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.